Jingfeng pharmaceutical, Yibai pharmaceutical's "abandoned child", plans to go on the market as a whole this year

Shanghai Jingfeng Pharmaceutical Co., Ltd., which was separated from Yibai Pharmaceutical (600594) four years ago, officially announced environmental protection on the website of the Ministry of environmental protection yesterday, from July 23 to 29 It is worth mentioning that the controlling shareholder of Jingfeng Pharmaceutical Co., Ltd is Ye Xiangwu, the former founder and chairman of Yibai Pharmaceutical Co., Ltd and Dou Qiling, the actual controller of Yibai Pharmaceutical Co., Ltd were once husband and wife To be listed as a whole This inspection is the first time for Jingfeng pharmaceutical in the Ministry of environmental protection The scope includes Jingfeng pharmaceutical, Guizhou Jingfeng injection and Guizhou Antai pharmaceutical These three companies belong to the inspection scope of heavy pollution industry The other three subsidiaries of Jingfeng pharmaceutical, Haimen Huiju pharmaceutical, Guizhou Jingfeng pharmaceutical and Shanghai Kexin biology, are not included in the environmental inspection Data shows that the main products of Jingfeng pharmaceutical are Shenxiong Glucose Injection (baisetong) and sodium hyaluronate injection (baibei), which are used for cardio cerebrovascular and orthopedic degenerative arthritis respectively At present, Jingfeng pharmaceutical has GMP certificates for small volume injections, APIs and tinctures Its sodium hyaluronate APIs and preparation workshops meet the requirements of modern GMP Meanwhile, Jingfeng pharmaceutical has 33 drug production approval numbers According to relevant data, Jingfeng pharmaceutical has become a famous pharmaceutical enterprise in Shanghai and Guizhou with a revenue of more than 1 billion yuan last year, and has a production base of more than 10000 square meters in both places According to the plan, Jingfeng pharmaceutical will be listed on the Shanghai stock exchange this year, involving 5 fund-raising projects, including 2 projects in Shanghai and 3 projects in Guizhou Up to the end of the verification, the projects invested by raised funds have obtained the corresponding EIA approval, but at present, none of them have been started and are in the proposed stage The reporter noted that at present, Jingfeng pharmaceutical's listing plan has not been officially included in the CSRC's review list, indicating that its listing process has not yet entered the critical stage According to normal procedures, Jingfeng pharmaceutical could not complete the overall listing within this year However, it is understood that Jingfeng pharmaceutical is actively promoting the material approval work When it comes to Jingfeng pharmaceutical, in fact, it has been immersed in the capital market for many years Before January 2009, Jingfeng pharmaceutical was the holding subsidiary of Yibai pharmaceutical At that time, Jingfeng Pharmaceutical Co., Ltd was named Shanghai baijiayi Pharmaceutical Co., Ltd., while Yibai pharmaceutical held 97.02% of its equity, while ye Xiangwu, chairman of Yibai pharmaceutical at that time, held 0.75% of its equity At that time, the operation of Jingfeng pharmaceutical was not smooth In the first 11 months of 2008, it had a loss of 1.92 million yuan, accumulated loss for many years was 32.72 million yuan, and its net assets were 90.9466 million yuan Finally, Yibai pharmaceutical transferred Jingfeng pharmaceutical as a whole on the basis of "integrating itself and getting rid of the burden" Ye Xiangwu was the convenient transferee Different from the current transfer of pharmaceutical assets at multiple premiums, Yibai pharmaceutical only sold Jingfeng pharmaceutical as a whole at a premium of 3.12 million yuan To the surprise of Yibai pharmaceutical, Shanghai baijiayi quickly turned around its losses and accumulated capital to rush to the market within four years Once husband and wife shop As an enterprise separated from Yibai pharmaceutical, a well-known listed pharmaceutical company, Jingfeng pharmaceutical's development speed in recent years is no less than that of Yibai pharmaceutical and other listed pharmaceutical companies, so that in the past two years, Jingfeng pharmaceutical has successively obtained strategic shares of vivo Hongda, vivo Baida equity fund and South China Sea growth fund under Zheng Weihe, a famous private placement tycoon in China From the perspective of investment and exit style of Zheng Weihe and his funds, there is no suspense for Jingfeng pharmaceutical to be listed In fact, the relationship between Jingfeng pharmaceutical and Yibai pharmaceutical is not so simple Ye Xiangwu, the actual controller of Jingfeng pharmaceutical, and Dou Qiling, the actual controller of Yibai pharmaceutical, were once husband and wife, and Yibai pharmaceutical was founded by both Yibai pharmaceutical was once called "husband and wife shop" when it was listed in 2004 At that time, Dou Qiling and ye Xiangwu were respectively the controlling shareholders and the second largest shareholder of Yibai pharmaceutical At one time, their shareholding ratio was as high as 40% Ye Xiangwu was also the legal representative of Shanghai baiplus one Although ye xiangwudang was only the second largest shareholder of Yibai pharmaceutical, he was once the chairman and general manager of Yibai pharmaceutical, while Dou Qiling, the controlling shareholder, retreated to the second tier Yibai pharmaceutical husband and wife shop has full effect However, in the first few years after its listing, Yibai pharmaceutical did not achieve high growth in performance In 2006, Yibai pharmaceutical lost 140 million yuan, so that Yibai pharmaceutical also spread a separate storm around 2006-2007, which attracted the attention of all parties The reporter learned from the relevant personnel of Yibai pharmaceutical that Dou Qiling and ye Xiangwu had actually divorced at that time, but the reasons for the divorce were not clear In July 2009, the personnel change of Yibai pharmaceutical was accelerated Ye Xiangwu resigned from the position of general manager of Yibai pharmaceutical, and he resigned from the position of chairman in January 2009 Since then, the control of Yibai pharmaceutical has been attributed to Dou Qiling During this period, ye Xiangwu continued to reduce his holding of Yibai pharmaceutical By the end of 2010, ye Xiangwu completely withdrew from the top ten shareholders of Yibai pharmaceutical However, ye Xiangwu is not a "pure person out of the home", and the transfer of Shanghai baiplus one has been regarded as one of the conditions for ye Xiangwu to withdraw from Yibai pharmaceutical It is only half a month before and after Yibai pharmaceutical plans to transfer Shanghai baiplus one, and then ye Xiangwu pays the first payment However, ye Xiangwu did not fully settle the transfer of Shanghai baiplus one until December 2011 Jian Weiguang and others left Yibai pharmaceutical at the same time as ye Xiangwu, the former vice president of Yibai pharmaceutical, and now the third natural person shareholder of Jingfeng pharmaceutical Interestingly, ye Xiangwu, who withdrew from Yibai pharmaceutical, managed Shanghai Baijia and promoted its listing Meanwhile, Yibai pharmaceutical's performance under Dou Qiling's control has continued to improve in recent years Last year, Yibai pharmaceutical had a revenue of more than 2.2 billion yuan and a net profit of 333 million yuan, which was in sharp contrast to Yibai pharmaceutical's huge loss in 2006.